Bleeding Outcomes After Percutaneous Coronary Intervention in the Past Two Decades in Japan　― From the CREDO-Kyoto Registry Cohort-2 and Cohort-3 ―

DOI DOI Web Site Web Site Web Site View 3 Remaining Hide 38 References Open Access

Bibliographic Information

Other Title
  • How to Prevent Bleeding Without Increased Risk of Thrombotic Events

Search this article

Description

<p>Background: Optimal intensity is unclear for P2Y12receptor blocker therapy after percutaneous coronary intervention (PCI) in real-world clinical practice.</p><p>Methods and Results: From the CREDO-Kyoto Registry, the current study population consisted of 25,419 patients (Cohort-2: n=12,161 and Cohort-3: n=13,258) who underwent their first PCI. P2Y12receptor blocker therapies were reduced dose of ticlopidine (200 mg/day), and global dose of clopidogrel (75 mg/day) in 87.7% and 94.8% of patients in Cohort-2 and Cohort-3, respectively. Cumulative 3-year incidence of GUSTO moderate/severe bleeding was significantly higher in Cohort-3 than in Cohort-2 (12.1% and 9.0%, P<0.0001). After adjusting 17 demographic factors and 9 management factors potentially related to the bleeding events other than the type of P2Y12receptor blocker, the higher bleeding risk in Cohort-3 relative to Cohort-2 remained significant (hazard ratio (HR): 1.52 95% confidence interval (CI) 1.37–1.68, P<0.0001). Cohort-3 compared with Cohort-2 was not associated with lower adjusted risk for myocardial infarction/ischemic stroke (HR: 0.96, 95% CI: 0.87–1.06, P=0.44).</p><p>Conclusions: In this historical comparative study, Cohort-3 compared with Cohort-2 was associated with excess bleeding risk, which might be at least partly explained by the difference in P2Y12receptor blockers.</p>

Journal

  • Circulation Journal

    Circulation Journal 86 (5), 748-759, 2022-04-25

    The Japanese Circulation Society

References(38)*help

See more

Keywords

Report a problem

Back to top